Effect of a Comprehensive Nutrition Support Product on the Nutritional Status of Adults With Inflammatory Bowel Disease
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Potassium, serum
研究概览
简要总结
Individuals with IBD are at risk for nutrient deficiencies. This prospective, non-randomized, open-label study will assess the effect of a nutrition support product on nutritional status in adults with IBD. Up to ten adults with ulcerative colitis or Crohn's disease will be enrolled in the study and asked to take the product for 12 weeks. The primary measures of the study are several blood markers of nutritional status.
详细描述
It is estimated that 1-1.3 million people in the United States suffer from the Inflammatory Bowel Diseases (IBD) Crohn's disease (CD) and Ulcerative colitis (UC). The pathophysiology of IBD involves malnutrition, malabsorption, altered intestinal permeability, inflammation, and gut flora alterations. Individuals with IBD are at risk for nutrient deficiencies due to decreased intake, decreased absorption and/or increased enteral losses. The most common deficiencies involve many micronutrients including vitamins and minerals; less commonly, adults may also be at risk for macronutrient deficiencies involving protein and total energy intake. The product being studied is a comprehensive nutrition support product that was formulated to meet the nutritional needs of individuals with digestive complaints. This study will assess the effect of the study product on blood markers of nutritional status in adults with IBD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-70
- •Ulcerative colitis or Crohn's disease (currently active/not considered in remission)
- •Willing to have blood drawn twice and willing to fast for 10-12 hours before blood draws
- •Able to speak, read and understand English
排除标准
- •Currently taking a nutrition support product (macronutrient/micronutrient support product consumed as a reconstituted beverage) or was taken within the last 28 days
- •Currently receiving intravenous nutrition support therapy (or within the last 28 days)
- •Currently taking curcumin, turmeric, fenugreek, hops, rosemary, ginger or quercetin (or they were taken within the last 14 days)
- •Currently taking anti-coagulant or anti-platelet prescription medications (or they were taken within the last 28 days)
- •Currently taking antibiotic, antiparasitic, or antifungal medications orally or intravenously (or they were taken within the last 28 days)
- •Initiation of or changes to supplements or medications within 28 days prior to screening
- •Initiation of or changes to an exercise regimen within 28 days prior to screening
- •Initiation of or changes to a food plan within 28 days prior to screening
- •Current involvement or within 28 days prior to screening of a significant diet or weight loss program
- •Hospitalization (for any reason other than a scheduled medical procedure) within 3 months prior to screening
- •Gastrointestinal surgery within 3 months prior to screening
- •Currently have a colostomy or ileostomy bag in place
- •Malignancy within the last 5 years (with the exception of basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ of the cervix)
- •Women who are lactating, pregnant or planning pregnancy within the next four months
- •Difficulty or aversion to taking powdered drink mixes or nutritional shakes
- •Currently participating in another interventional research study or participated in another interventional study within the previous 28 days
研究组 & 干预措施
Nutrition Support Product
Participants will be asked to take a nutrition support product twice per day for a period of 12 weeks.
干预措施: Nutrition support product (Other)
结局指标
主要结局
Potassium, serum
时间窗: Baseline, 12 weeks
Mean change, pre-to-post treatment, will be assessed.
Overall nutritional status
时间窗: Baseline, 12 weeks
The effect on overall nutritional status will be determined by aggregating data from multiple measures (albumin, red blood cell count, hemoglobin, hematocrit, vitamin B12, folate, sodium, potassium and calcium) into one reported value. The proportion (percentage) of abnormal values present at baseline will be calculated and compared to the proportion of abnormal values present at the end of the study. Mean change, pre-to-post treatment, will also be assessed for each individual measure.
Albumin, serum
时间窗: Baseline, 12 weeks
Mean change, pre-to-post treatment, will be assessed.
Hematocrit
时间窗: Baseline, 12 weeks
Mean change, pre-to-post treatment, will be assessed.
Vitamin B12, serum
时间窗: Baseline, 12 weeks
Mean change, pre-to-post treatment, will be assessed.
Sodium, serum
时间窗: Baseline, 12 weeks
Mean change, pre-to-post treatment, will be assessed.
Folate, serum
时间窗: Baseline, 12 weeks
Mean change, pre-to-post treatment, will be assessed.
Calcium, serum
时间窗: Baseline, 12 weeks
Mean change, pre-to-post treatment, will be assessed.
Red blood cell count
时间窗: Baseline, 12 weeks
Mean change, pre-to-post treatment, will be assessed.
Hemoglobin
时间窗: Baseline, 12 weeks
Mean change, pre-to-post treatment, will be assessed.
次要结局
未报告次要终点
研究者
Jennifer Ryan
Postdoctoral Fellow
National University of Natural Medicine